ClinicalTrials.gg

Program

voclosporin

Also written as “LX211”, “Voclosporin” and “LUPKYNIS”.

Its studies are mostly in Lupus Nephritis · Psoriasis · Keratoconjunctivitis Sicca · Uveitis, Posterior · Glomerulosclerosis, Focal Segmental, led by 3 companies.

Furthest: phase 4, since May 13, 202623 company-led studies, 2 open or runningNext primary completion: Jun 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Aurinia Pharmaceuticals171 open or runningphase 4since May 13, 2026Oct 25, 2005Mar 2, 2029phase 4 · NCT07611214
Lux Biosciences50 open or runningphase 3since Nov 27, 2006Nov 27, 2006none ahead
Qilu Pharmaceutical11 open or runningphase 3since Mar 20, 2024Mar 20, 2024Jun 2027phase 3 · NCT06406205

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 9 studies since Oct 25, 2005.

  1. Apr 25, 2012Phase 3 study in Renal TransplantationAurinia Pharmaceuticals · NCT01586845
  2. May 14, 2014Phase 2 study in Lupus NephritisAurinia Pharmaceuticals · NCT02141672 · 265 enrolled · United States, Bangladesh, Belarus and more
  3. Oct 20, 2016Phase 1 study in VolunteersAurinia Pharmaceuticals · NCT02949999 · 40 enrolled · Philippines
  4. Oct 26, 2016Phase 2 study in Lupus NephritisAurinia Pharmaceuticals · NCT02949973 · 10 enrolled · Malaysia
  5. Jan 12, 2017Phase 3 study in Lupus NephritisAurinia Pharmaceuticals · NCT03021499 · 358 enrolled · United States, Argentina, Belarus and more
  6. Jun 14, 2018Phase 2 study in Glomerulosclerosis, Focal SegmentalAurinia Pharmaceuticals · NCT03598036 · 5 enrolled · United States, Dominican Republic
  7. Jun 25, 2018Phase 3 study in Lupus NephritisAurinia Pharmaceuticals · NCT03597464 · 216 enrolled · United States
  8. Jul 13, 2018Phase 2 study in Dry Eye SyndromesAurinia Pharmaceuticals · NCT03597139 · 100 enrolled · United States
  9. Oct 30, 2019Phase 3 study in Dry Eye SyndromesAurinia Pharmaceuticals · NCT04147650 · 508 enrolled · United States
  10. Feb 7, 2022Phase 1 study in Drug-drug InteractionAurinia Pharmaceuticals · NCT05306379 · 24 enrolled · United States
  11. Mar 11, 2022Phase 3 study in Lupus NephritisAurinia Pharmaceuticals · NCT05288855 · 9 enrolled · United States, Colombia, Japan and more
  12. Jun 21, 2023Phase 3 study in Lupus NephritisAurinia Pharmaceuticals · NCT05962788 · 4 enrolled · United States, Colombia, Japan and more
  13. Mar 20, 2024Qilu Pharmaceutical’s first study: phase 3 study in Lupus NephritisNew to Qilu PharmaceuticalQilu Pharmaceutical · NCT06406205 · 270 planned · China
  14. May 13, 2026Phase 4 study in Lupus NephritisAurinia Pharmaceuticals · NCT07611214 · 150 planned · United States

Ahead

  1. Jun 2027Primary completion: phase 3 study in Lupus NephritisQilu Pharmaceutical · NCT06406205
  2. Mar 2, 2029Primary completion: phase 4 study in Lupus NephritisAurinia Pharmaceuticals · NCT07611214

TargetBeta

PPP3CA →read by rule
“Serine/threonine protein phosphatase 2B catalytic subunit, alpha isoform inhibitor”ChEMBL 37, by rule

Studies

All 23 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07611214Lupus Nephritis · United States4RecruitingAurinia PharmaceuticalsMar 2, 2029150
NCT06406205Lupus Nephritis · China3RecruitingQilu PharmaceuticalJun 2027270
NCT05962788Lupus Nephritis · United States, Colombia, Japan and more3TerminatedAurinia PharmaceuticalsJul 4, 20254
NCT05288855Lupus Nephritis · United States, Colombia, Japan and more3TerminatedAurinia PharmaceuticalsJul 3, 20259
NCT05306379Drug-drug Interaction · United States1CompletedAurinia PharmaceuticalsApr 5, 202224
NCT04147650Dry Eye Syndromes · United States3CompletedAurinia PharmaceuticalsSep 17, 2020508
NCT03597139Dry Eye Syndromes · United States2CompletedAurinia PharmaceuticalsNov 9, 2018100
NCT03597464Lupus Nephritis · United States3CompletedAurinia PharmaceuticalsOct 7, 2021216
NCT03598036Glomerulosclerosis, Focal Segmental · United States, Dominican Republic2TerminatedAurinia PharmaceuticalsMay 19, 20205
NCT03021499Lupus Nephritis · United States, Argentina, Belarus and more3CompletedAurinia PharmaceuticalsSep 24, 2019358
NCT02949973Lupus Nephritis · Malaysia2CompletedAurinia PharmaceuticalsDec 201610
NCT02949999Volunteers · Philippines1CompletedAurinia PharmaceuticalsDec 201640
NCT02141672Lupus Nephritis · United States, Bangladesh, Belarus and more2CompletedAurinia PharmaceuticalsJul 2016265
NCT01586845Renal Transplantation3WithdrawnAurinia PharmaceuticalsDec 20150
NCT01243983Noninfectious Uveitis · United States, Austria, Brazil and more3CompletedLux BiosciencesDec 2012155
NCT00851734Keratoconjunctivitis Sicca · United States1CompletedLux BiosciencesMar 200935
NCT00408187Psoriasis · Canada, Germany, Poland3CompletedAurinia PharmaceuticalsDec 2008642
NCT00404885Uveitis, Anterior · United States, Austria, Canada and more3CompletedLux BiosciencesNov 2008108
NCT00404742Uveitis, Posterior · United States, Austria, Canada and more3CompletedLux BiosciencesNov 2008232
NCT00404612Uveitis, Posterior · United States, Austria, Canada and more3CompletedLux BiosciencesNov 2008218
NCT00270634Kidney Diseases · United States, Canada2CompletedAurinia PharmaceuticalsJul 2009334
NCT00258713Psoriasis · Canada3CompletedAurinia PharmaceuticalsJul 2006309
NCT00244842Psoriasis · Canada3CompletedAurinia PharmaceuticalsOct 2005451

How it is read

Names in the registry

  • “LX211”, 10 entries
  • “Voclosporin”, 7 entries
  • “voclosporin”, 6 entries
  • “LUPKYNIS”, 1 entry
  • “Voclosporin(QL1074)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.